Possible Mpox Protection from Smallpox Vaccine–Generated Antibodies among Older Adults
Iván Sanz-Muñoz, Laura Sánchez-de Prada, Javier Sánchez‐Martínez, Silvia Rojo‐Rello, Marta Domínguez‐Gil, Cristina Hernán-García, V. Fernández Espinilla, Raúl Ortiz de Lejarazu-Leonardo, Javier Castrodeza-Sanz, José María Eirós Bouza
Abstract
Smallpox vaccination may confer cross-protection to mpox. We evaluated vaccinia virus antibodies in 162 persons ≥50 years of age in Spain; 68.5% had detectable antibodies. Highest coverage (78%) was among persons 71-80 years of age. Low antibody levels in 31.5% of this population indicates that addressing their vaccination should be a priority.
Topics & Concepts
SmallpoxVacciniaVaccinationAntibodyMedicineSmallpox vaccineVirologyImmunologySmallpox virusVirusPopulationBiologyEnvironmental healthBiochemistryRecombinant DNAGenePoxvirus research and outbreaksVirology and Viral DiseasesImmunotherapy and Immune Responses